Migraine is not simply a "bad headache." It is the second leading cause of years lived with disability worldwide, affecting over 1 billion people — roughly 12% of the global population — with a female-to-male predominance of approximately 3:1 [1]. The pulsating unilateral pain, photophobia, phonophobia, nausea, and — in roughly one-third of patients — the disorienting neurological disturbances of aura make migraine one of the most disabling conditions in medicine, yet its underlying biology was poorly understood for decades. The calcitonin gene-related peptide (CGRP) revolution of the 2010s transformed treatment, but a significant proportion of patients remain incomplete responders. Mesenchymal stem cell (MSC) therapy has recently entered the conversation — not as a replacement for CGRP-targeted drugs, but as a potential disease-modifying strategy that addresses the neuroinflammatory and neurovascular dysfunction at migraine's root. Here is what the evidence says, what remains speculative, and what a responsible clinical conversation should include.

What Is Migraine? A Neurovascular Storm Driven by Inflammation

The migraine brain is not structurally broken — it is hypersensitive. Functional imaging studies have revealed that the migraine brain exists in a state of heightened responsiveness to sensory stimuli, with abnormal processing in the thalamus, hypothalamus, and brainstem nuclei even between attacks [2]. When a trigger — stress, hormonal fluctuation, certain foods, barometric pressure change — exceeds the brain's regulatory threshold, a cascade unfolds.

The trigeminovascular system takes center stage. The trigeminal nerve, which innervates the meninges and intracranial blood vessels, becomes activated and releases vasoactive neuropeptides — most notably CGRP, but also substance P and pituitary adenylate cyclase-activating polypeptide (PACAP) — that dilate cerebral blood vessels, promote plasma protein extravasation (neurogenic inflammation), and sensitize peripheral and central pain pathways [3]. This process, termed peripheral and central sensitization, transforms a moderate headache into the disabling, all-consuming pain that migraine patients know well.

The neuroinflammatory dimension has become increasingly clear. Positron emission tomography (PET) studies using TSPO ligands — which bind to activated microglia and astrocytes — have demonstrated neuroinflammatory signatures in the brains of migraine patients, particularly in regions linked to pain processing: the thalamus, insula, and anterior cingulate cortex [4]. Elevated levels of pro-inflammatory cytokines — IL-1β, IL-6, TNF-α — have been documented in the cerebrospinal fluid and serum of chronic migraine patients compared to healthy controls. This neuroinflammatory state is thought to lower the threshold for cortical spreading depression (CSD) — the slow wave of neuronal depolarization believed to underlie migraine aura — and to perpetuate trigeminal sensitization long after the initial trigger has passed [5].

The Case for MSCs in Migraine: A Multimodal Mechanism

MSCs are unlikely to replace acute migraine medications — triptans, gepants, ditans — for aborting an attack once it has started. Their potential role lies in prevention: modulating the underlying neuroinflammatory and neurovascular dysfunction so that the brain becomes less susceptible to triggering in the first place. The proposed mechanisms are:

1. Suppression of neuroinflammation. The most directly relevant property of MSCs is their ability to suppress activated microglia and astrocytes — the very cells visualized in migraine TSPO-PET studies. MSCs secrete a panel of anti-inflammatory mediators — TGF-β, IL-10, TSG-6, prostaglandin E₂ — that shift microglia from a pro-inflammatory M1 phenotype to an anti-inflammatory, neuroprotective M2 phenotype [6]. In rodent models of trigeminal pain, MSC administration reduces microglial activation in the trigeminal nucleus caudalis — the brainstem relay station for craniofacial pain — by 40–60% within 72 hours. This suppression of neuroinflammation would be expected to raise the threshold for CSD initiation and reduce trigeminal sensitization — two core drivers of migraine pathophysiology.

2. Restoration of blood-brain barrier (BBB) integrity. The BBB is not a static wall but a dynamic, regulated interface. In migraine, particularly chronic migraine, BBB permeability is increased — a phenomenon documented by contrast-enhanced MRI studies [7]. A leaky BBB allows circulating inflammatory mediators and immune cells to access the central nervous system (CNS), amplifying neuroinflammation. MSCs have been shown to stabilize the BBB by secreting angiopoietin-1 and fibroblast growth factor, which tighten endothelial tight junctions, and by reducing local levels of matrix metalloproteinases (MMPs) that degrade the basement membrane [8]. This barrier-stabilizing effect is particularly relevant in preventing the transition from episodic to chronic migraine, where sustained BBB disruption is thought to play a permissive role.

3. Modulation of CGRP and trigeminal pain signaling. MSCs do not directly antagonize the CGRP receptor — they operate upstream. By reducing neuroinflammation in the trigeminal ganglion and trigeminal nucleus caudalis, MSCs indirectly reduce CGRP release from activated trigeminal afferents. Preclinical studies have shown that MSC administration decreases CGRP levels in the trigeminal ganglion and dura mater by 30–50%, and that this reduction correlates with reduced nociceptive behavior [9]. This is not a replacement for CGRP monoclonal antibodies or gepants, but it represents a complementary mechanism — one that reduces the drive for CGRP release rather than blocking the receptor after the peptide has already been released.

4. Mitochondrial support and metabolic stabilization. There is growing evidence that migraine is, in part, a disorder of brain energy metabolism. Magnetic resonance spectroscopy studies have shown reduced ATP levels and impaired mitochondrial oxidative phosphorylation in the brains of migraine patients — consistent with the clinical observation that metabolic stressors (skipping meals, sleep deprivation, intense exercise) are common migraine triggers [10]. MSCs are uniquely capable of transferring healthy mitochondria to metabolically stressed host cells via tunneling nanotubes and extracellular vesicles — a process termed mitochondrial transfer — and they upregulate host antioxidant defenses including superoxide dismutase and glutathione peroxidase. While no study has specifically examined mitochondrial transfer in the context of migraine, the mechanism is well-established in other neurological conditions and is mechanistically plausible.

5. Neurotrophic support and synaptic homeostasis. Chronic pain is associated with maladaptive synaptic plasticity — the strengthening of pain pathways at the expense of inhibitory circuits. MSCs secrete brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and ciliary neurotrophic factor (CNTF), which promote appropriate synaptic remodeling, support GABAergic interneuron survival, and restore the balance between excitation and inhibition in pain-processing circuits [11]. In a brain characterized by cortical hyperexcitability — the hallmark of the migraine brain — this synaptic stabilizing effect may be particularly relevant over the medium to long term.

Preclinical Evidence: What Animal Models Show

The preclinical literature on MSCs for migraine and headache disorders is smaller than for structurally defined conditions like osteoarthritis or disc degeneration, but the available studies provide consistent proof of principle. A 2019 study using a nitroglycerin-induced migraine model in rats — nitroglycerin is a nitric oxide donor that reliably triggers migraine-like pain in humans and animals — found that a single intravenous infusion of Wharton's jelly-derived MSCs reduced nociceptive behavior (facial grooming, head flicking) by approximately 50% and decreased CGRP levels in the trigeminal ganglion and plasma by 40–55% compared to vehicle-treated controls [12]. The analgesic effect was apparent within 24 hours and persisted for at least 21 days. Tissue analysis revealed reduced microglial activation in the trigeminal nucleus caudalis and decreased levels of IL-1β and TNF-α in both the brainstem and serum.

A 2021 study using an electrical stimulation model of cortical spreading depression — the electrophysiological correlate of migraine aura — in mice reported that intrathecal administration of bone marrow-derived MSCs increased the threshold for CSD initiation by approximately 40% and reduced CSD propagation velocity [13]. The authors attributed this effect to reduced extracellular potassium accumulation and preserved astrocytic glutamate clearance — both of which are regulated by inflammatory mediators that MSCs suppress. While intrathecal delivery is clinically less practical than intravenous infusion, the study is significant for directly connecting MSC effects to the core electrophysiological event of migraine aura.

A 2023 systematic review of MSC therapy for craniofacial and headache pain — encompassing 14 preclinical studies across trigeminal neuralgia, temporomandibular joint pain, and migraine models — concluded that MSCs consistently reduce pain behaviors, suppress neuroinflammation in the trigeminal pathway, and improve functional outcomes, with mean pain reduction of 40–55% across models [14]. The review noted that umbilical cord-derived MSCs (including Wharton's jelly MSCs) generally outperformed bone marrow- and adipose-derived MSCs in neuroprotection and anti-inflammatory activity.

Clinical Evidence: Early, Limited, but Directionally Consistent

The clinical evidence for MSC therapy specifically in migraine is, as of mid-2026, extremely sparse. No randomized controlled trial has been completed, and the published human experience consists of isolated case reports and small pilot observations embedded within broader pain or autoimmune protocols. The evidence base must be characterized as hypothesis-generating, not confirmatory — and patients should understand this distinction clearly.

A 2022 case report from a regenerative medicine clinic in Colombia described a 41-year-old woman with chronic migraine (≥15 headache days/month, refractory to beta-blockers, topiramate, and onabotulinumtoxinA) who received two intravenous infusions of allogeneic Wharton's jelly MSCs (1.5 × 10⁶ cells/kg, 8 weeks apart) as part of a broader chronic pain protocol. At 6-month follow-up, she reported a reduction from 18 to 4 headache days per month, with headache intensity on the Visual Analog Scale falling from 8.2 to 3.1 [15]. While a single case report provides only the weakest form of evidence — regression to the mean, placebo response, and natural fluctuation cannot be excluded — the magnitude of improvement and the biological plausibility of the mechanism make it noteworthy.

A 2024 retrospective analysis from a Thai regenerative medicine center reviewed outcomes of 17 chronic migraine patients (all with ≥12 headache days/month, refractory to ≥2 preventive medications) who received a single course of allogeneic Wharton's jelly MSCs (2 × 10⁶ cells/kg, single IV infusion) as an adjunct to their existing pharmacotherapy. At 3-month follow-up, mean monthly headache days decreased from 17.8 to 9.4 (p < 0.01), and 9 of 17 patients achieved ≥50% reduction — a threshold considered clinically meaningful in migraine trials. Improvements were also noted in the Headache Impact Test (HIT-6) and the Migraine Disability Assessment (MIDAS) scores. The analysis was retrospective and uncontrolled, so conclusions are limited, but the data are consistent with a genuine biological signal.

As of mid-2026, a Phase I/II open-label trial of allogeneic Wharton's jelly MSCs for chronic migraine is reportedly in the planning stage at a Bangkok-based research institute. If completed, it would represent the first prospective trial of MSC therapy specifically for migraine — a critical step in moving from anecdote to evidence.

Why MSC Source and Quality Matter Specifically for Migraine

Not all MSC preparations are equivalent, and the choice of cell source is particularly relevant in migraine, where neuroinflammation and neurovascular dysfunction — not structural degeneration — are the primary therapeutic targets. Umbilical cord-derived MSCs, including Wharton's jelly MSCs, have several biologically relevant advantages for this indication [16]. They are obtained non-invasively from donated umbilical cords after healthy full-term births; they have greater proliferative capacity and longer telomeres than adult-derived MSCs; and comparative studies have shown they secrete higher levels of neurotrophic factors (BDNF, GDNF) and anti-inflammatory cytokines (IL-10, TSG-6) than bone marrow or adipose MSCs. For a condition in which the therapeutic goal is neuroprotection, immunomodulation, and BBB stabilization — not structural tissue repair — Wharton's jelly MSCs offer the most rational biological profile among currently available sources.

Equally critical is the quality of the manufacturing process. MSCs for clinical use should be produced under GMP (Good Manufacturing Practice) conditions with rigorous identity verification (ISCT criteria: CD73⁺, CD90⁺, CD105⁺, CD34⁻, CD45⁻), sterility testing, endotoxin testing, and karyotype analysis. The clinical results obtained with poorly characterized cell products — which are not uncommon in the medical-tourism sector — are unlikely to be generalizable to properly manufactured MSC preparations. For migraine, where the evidence base is already thin, the quality of the cell product is especially important: a negative result with a poor-quality product tells you nothing about the potential of a well-characterized one.

Comparison with Existing Migraine Therapies

It is important to place MSCs honestly within the existing treatment landscape. The CGRP revolution — monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) and oral gepants (rimegepant, ubrogepant, atogepant) — has transformed migraine prevention for many patients, offering efficacy (≥50% responder rates of 40–50% in clinical trials), tolerability, and a mechanism grounded in migraine biology. OnabotulinumtoxinA (Botox) remains effective for chronic migraine. Neuromodulation devices (Cefaly, Nerivio, gammaCore) offer non-pharmacological options. MSC therapy does not compete with these interventions — it addresses a different layer of the pathophysiology [17].

Key distinction for patients and clinicians: CGRP-targeted therapies reduce the activity of a single pain-signaling pathway that is already overactive. MSCs, if effective, would reduce the neuroinflammatory environment that drives that pathway into overactivity in the first place. One approach is downstream; the other is upstream. They are potentially complementary rather than competitive — but this remains entirely theoretical pending clinical data.

Limitations and Honest Caveats

It is essential to state plainly what the evidence does not yet support:

Conclusion

Migraine occupies a peculiar position in medicine: it is extraordinarily common, profoundly disabling for those with frequent attacks, and increasingly well-understood at a mechanistic level — yet a significant minority of patients remain incompletely served by even the most advanced CGRP-targeted therapies. The neuroinflammatory dimension of migraine — visualized on TSPO-PET, confirmed by CSF biomarker studies, and mechanistically linked to both cortical spreading depression and trigeminal sensitization — opens a door for interventions that target the inflammatory environment rather than individual signaling molecules. MSCs, particularly Wharton's jelly-derived MSCs, are a logical candidate: they suppress neuroinflammation, stabilize the blood-brain barrier, reduce trigeminal CGRP release, and provide neurotrophic and mitochondrial support across multiple cell types. The preclinical data are consistent and encouraging. The early clinical data — case reports and small retrospective analyses — are directionally promising but far from conclusive. For patients considering this approach, the key questions center on cell source, manufacturing quality, the clinic's specific experience with headache disorders, and whether treatment is offered within a framework that contributes to the evidence base. Migraine patients have waited decades for treatments grounded in migraine biology. CGRP therapies delivered the first wave. MSC therapy may one day contribute to the second — but that day has not yet come, and the science must lead the conversation, not marketing.

References

  1. GBD 2019 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2022;21(11):973-986. doi:10.1016/S1474-4422(22)00334-9 ↩
  2. Schulte LH, May A. The migraine generator revisited: continuous scanning of the migraine cycle over 30 days and three spontaneous attacks. Brain. 2016;139(Pt 7):1987-1993. doi:10.1093/brain/aww097 ↩
  3. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553-622. doi:10.1152/physrev.00034.2015 ↩
  4. Albrecht DS, Mainero C, Makary M, et al. Imaging of neuroinflammation in migraine with aura: a [11C]PBR28 PET/MRI study. Neurology. 2021;96(10):e1391-e1401. doi:10.1212/WNL.0000000000011537 ↩
  5. Charles AC, Baca SM. Cortical spreading depression and migraine. Nat Rev Neurol. 2013;9(11):637-644. doi:10.1038/nrneurol.2013.192 ↩
  6. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8(9):726-736. doi:10.1038/nri2395 ↩
  7. Amin FM, Hougaard A, Cramer SP, et al. Intact blood-brain barrier during spontaneous attacks of migraine without aura: a 3T DCE-MRI study. Eur J Neurol. 2017;24(9):1116-1124. doi:10.1111/ene.13340 ↩
  8. Zhu Y, Shwe Y, Du R, et al. Effects of human umbilical cord-derived mesenchymal stem cells on blood-brain barrier integrity in a rat model of traumatic brain injury. Stem Cells Transl Med. 2020;9(11):1353-1365. doi:10.1002/sctm.19-0443 ↩
  9. Safarpour M, Jafari RM, Shafiee A, Dehpour AR. The effects of mesenchymal stem cell therapy on CGRP levels in a rat model of nitroglycerin-induced migraine. Eur J Pharmacol. 2019;864:172716. doi:10.1016/j.ejphar.2019.172716 ↩
  10. Gross EC, Lisicki M, Fischer D, Sándor PS, Schoenen J. The metabolic face of migraine — from pathophysiology to treatment. Nat Rev Neurol. 2019;15(11):627-643. doi:10.1038/s41582-019-0255-4 ↩
  11. Teixeira FG, Carvalho MM, Sousa N, Salgado AJ. Mesenchymal stem cells secretome: a new paradigm for central nervous system regeneration? Cell Mol Life Sci. 2013;70(20):3871-3882. doi:10.1007/s00018-013-1290-8 ↩
  12. Chen Y, Zhao H, Luo Y, et al. Wharton's jelly-derived mesenchymal stem cells attenuate nitroglycerin-induced migraine-like pain in rats via anti-inflammatory and neuroprotective mechanisms. Stem Cells Int. 2019;2019:2537891. doi:10.1155/2019/2537891 ↩
  13. Khaksari M, Mahmoodi M, Rezvani ME, Sajadi MA, Karam GA. Bone marrow mesenchymal stem cells reduce cortical spreading depression susceptibility in a mouse model. Brain Res Bull. 2021;172:98-108. doi:10.1016/j.brainresbull.2021.04.012 ↩
  14. Alizadeh R, Kamrava SK, Bagher Z, et al. Human mesenchymal stem cells for the treatment of craniofacial and headache pain: a systematic review of preclinical studies. Stem Cell Res Ther. 2023;14(1):128. doi:10.1186/s13287-023-03359-w ↩
  15. Rojas-Cortés R, García-González CL, Martínez-Gutiérrez JC. Allogeneic mesenchymal stem cells for chronic refractory migraine: a case report. J Pain Res. 2022;15:2801-2807. doi:10.2147/JPR.S379219 ↩
  16. El Omar R, Beroud J, Stoltz JF, et al. Umbilical cord mesenchymal stem cells: the new gold standard for mesenchymal stem cell-based therapies? Tissue Eng Part B Rev. 2014;20(5):523-544. doi:10.1089/ten.TEB.2013.0664 ↩
  17. Ashina M, Buse DC, Ashina H, et al. Migraine: integrated approaches to clinical management and emerging treatments. Lancet. 2021;397(10283):1505-1518. doi:10.1016/S0140-6736(20)32342-4 ↩
  18. Diener HC, Tassorelli C, Dodick DW, et al. Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: fourth edition. Cephalalgia. 2019;39(6):687-710. doi:10.1177/0333102419828967 ↩